Trial Profile
Study of Advate in patients with hemophilia A in a postmarketing surveillance in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- 01 Jan 2019 Results of post hoc analysis assessing safety, and efficacy of Advate in previously untreated patients with hemophilia A, published in the International Journal of Hematology.
- 05 Sep 2018 New trial record